Cannabis Science Conference Returns to Portland, Oregon with Renewed Focus on Analytical, Medical, Cultivation, and Psychedelic Scientific Insights
The 2023 Portland show will include four tracks–analytical science, medical cannabis, cultivation, psychedelics–plus a discussion on medical cannabis for veterans, and more!
Cannabis Science Conference (CSC), the premier cannabis science conference event focusing on analytical science, medical cannabis, cultivation, and psychedelics, announced today the return of their groundbreaking event to Portland, Oregon from April 19-21, 2023, a location which is perfectly positioned as a hotbed of cannabis activity and interest, and the epicenter of the new and emerging psychedelic market.
“Portland, Oregon is a natural fit for our Spring 2023 Cannabis Science Conference, with its established cannabis and medical markets, and openness toward emerging markets such as psychedelics,” said Megan L’Heureux, spokesperson for CSC, and the group editorial director of Cannabis Science and Technology and Cannabis Patient Care magazines. “CSC’s goal is to spread information and empowerment through education, and we are bringing a hard-hitting team of professional experts to share knowledge and have in-depth conversations about how to move these niche industries forward. We look forward to tackling topics like using psychedelics and medical cannabis to help veterans and other patient demographics as well as our core topic areas focused on analytical testing and cultivation. Our agenda will hit every topic our audience has been asking to learn more about.”
The agenda will include four main program tracks, with professional expert chairs including Analytical chair Dr. Julie Kowalski, a technical consultant serving the cannabis and hemp testing markets; Cultivation chair Dr. Zacariah L. Hildenbrand, who sits on the Editorial Advisory Board of Cannabis Science and Technology; Medical chair Cherissa Jackson, who served 23 years of active-duty military service with 10 years as a US Air Force Nurse; and Psychedelics chair Dr. Denise Vidot, an epidemiologist at the University of Miami where she is Founder of the International Cannabis and Psychedelic Research Collaborative.
The show will feature several key sessions, including:
- “Low and Ultra-Low Doses of Cannabinoids: Are We Missing the Sweet Spot?” by Dr. Dustin Sulak, DO, Healer.com
- “MDMA/Psychedelic-Assisted Therapy: The Path to Potential FDA Approval” by Dr. Sue Sisley, MD, President of Scottsdale Research Institute (SRI) and President/Founder of Field to Healed Foundation
- A panel discussion on “Results from the First NIH Funded Population-based Study of Medical Marijuana”
- A panel discussion on “Quality Assurance and Safety in Cannabis, Psilocybin, and Hemp”
- A film screening of the movie Unprescribed, and a conversation on the increasing numbers of veterans are turning to cannabis as a safer alternative to pharmaceuticals by filmmaker Steve Ellmore
For the full show agenda and to register, please visit the CSC website.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
